<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consortium PSYCHIATRICUM</journal-id><journal-title-group><journal-title xml:lang="en">Consortium PSYCHIATRICUM</journal-title><trans-title-group xml:lang="ru"><trans-title>Consortium PSYCHIATRICUM</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2712-7672</issn><issn publication-format="electronic">2713-2919</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">13622</article-id><article-id pub-id-type="doi">10.17816/CP13622</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CASE REPORT</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ СЛУЧАЙ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Endoxifen in Treatment of Individuals with Borderline Personality Disorder with Predominant Impulsivity: A Case Series</article-title><trans-title-group xml:lang="ru"><trans-title>Применение эндоксифена при пограничном расстройстве личности с выраженной импульсивностью: серия клинических случаев</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8152-9798</contrib-id><contrib-id contrib-id-type="scopus">57191832268</contrib-id><name-alternatives><name xml:lang="en"><surname>Banerjee</surname><given-names>Debanjan</given-names></name><name xml:lang="ru"><surname>Банерджи</surname><given-names>Дебанджан</given-names></name></name-alternatives><address><country country="IN">India</country></address><bio xml:lang="en"><p>MD, Consultant Geriatric Psychiatrist</p></bio><bio xml:lang="ru"><p>консультант по гериатрической психиатрии</p></bio><email>dr.djan88@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ray</surname><given-names>Rajashree</given-names></name><name xml:lang="ru"><surname>Рэй</surname><given-names>Раджашри</given-names></name></name-alternatives><address><country country="IN">India</country></address><bio xml:lang="en"><p>Associate Professor, Department of Psychiatry</p></bio><bio xml:lang="ru"><p>доцент, кафедра психиатрии</p></bio><email>drrajashree.ray@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Apollo Gleneagles Multispecialty Hospitals</institution></aff><aff><institution xml:lang="ru">Многопрофильная больница Аполло Глениглс</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Gauri Devi Institute of Medical Sciences and Hospital</institution></aff><aff><institution xml:lang="ru">Институт медицинских наук и больница Гаури Деви</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-12-14" publication-format="electronic"><day>14</day><month>12</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-12-22" publication-format="electronic"><day>22</day><month>12</month><year>2023</year></pub-date><volume>4</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>66</fpage><lpage>73</lpage><history><date date-type="received" iso-8601-date="2023-08-23"><day>23</day><month>08</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-12-14"><day>14</day><month>12</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Banerjee D., Ray R.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Банерджи Д., Рэй Р.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Banerjee D., Ray R.</copyright-holder><copyright-holder xml:lang="ru">Банерджи Д., Рэй Р.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consortium-psy.com/jour/article/view/13622">https://consortium-psy.com/jour/article/view/13622</self-uri><abstract xml:lang="en"><p>Endoxifen, a protein kinase C inhibitor, has been approved for use in manic episodes in India. One of the symptom traits that it predominantly targets is impulsivity. Impulsivity can also be a symptom dimension of other mental health conditions, one of which is Borderline Personality Disorder (BPD). Management of BPD is challenging, with limited pharmacological options that are symptom-directed and psychotherapy sessions that are fraught with early dropouts and lack of compliance. Impulsive behaviors represent a major reason for seeking help in BPD, especially with regard to non-suicidal self-injury, substance abuse, high-risk sexual behavior, aggression, etc. Here, we present a case series comprising five individuals with a diagnosis of BPD whose treatment regimens were changed and endoxifen added at a dose of 8 mg once daily. Clinical improvement was monitored using the Borderline Evaluation of Severity Over Time (BEST). All the subjects improved in the impulsivity domains as well as with regard to attention deficits, mood fluctuations, and overall functioning. Endoxifen is thus potential promising in terms of the management of BPD, but needs more extensive study to fully substantiate its clinical benefits.</p></abstract><trans-abstract xml:lang="ru"><p>Эндоксифен, ингибитор протеинкиназы С, был одобрен в Индии для применения при маниакальных эпизодах. Импульсивность — один из симптомов, на который преимущественно направлено действие данного вещества. Импульсивность присуща различным психическим расстройствам, одним из которых является пограничное расстройство личности (ПРЛ). Лечение ПРЛ является сложной задачей, поскольку фармакологические средства, направленные на устранение симптомов, ограничены, а сеансы психотерапии могут спровоцировать прекращение лечения на ранней стадии и несоблюдение режима терапии. При ПРЛ импульсивное поведение зачастую является первопричиной обращения за помощью, особенно при несуицидальном самоповреждающем поведении, злоупотреблением психоактивных веществ, рискованным сексуальным поведением, агрессией и т.д. В данной статье представлена серия из пяти клинических случаев пациентов с диагностированным ПРЛ, которым в схему лечения был добавлен эндоксифен в дозе 8 мг один раз в день. Клиническая динамика отслеживалось с помощью опросника Динамической оценки тяжести проявлений пограничного расстройства личности (Borderline Evaluation of Severity Over Time, BEST). У всех испытуемых улучшились показатели в отношении импульсивности, дефицита внимания, колебаний настроения и общего функционирования. Таким образом, эндоксифен является потенциально перспективным препаратом для лечения ПРЛ, но для полного подтверждения его клинических преимуществ необходимы более обширные исследования.</p></trans-abstract><kwd-group xml:lang="en"><kwd>borderline personality disorder</kwd><kwd>impulsivity</kwd><kwd>protein kinase C</kwd><kwd>endoxifen</kwd><kwd>case series</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>пограничное расстройство личности</kwd><kwd>импульсивность</kwd><kwd>протеинкиназа C</kwd><kwd>эндоксифен</kwd><kwd>серия клинических случаев</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Bozzatello P, Rocca P, De Rosa ML, Bellino S. Current and emerging medications for borderline personality disorder: is pharmacotherapy alone enough? Expert Opin Pharmacother. 2020;21(1):47–61. doi: 10.1080/14656566.2019.1686482.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Guilé JM, Boissel L, Alaux-Cantin S, de La Rivière SG. Borderline personality disorder in adolescents: prevalence, diagnosis, and treatment strategies. Adolesc Health Med Ther. 2018;9:199–210. doi: 10.2147/AHMT.S156565.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Choi-Kain LW, Finch EF, Masland SR, et al. What works in the treatment of borderline personality disorder. Curr Behav Neurosci Rep. 2017;4(1):21–30. doi: 10.1007/s40473-017-0103-z.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Leichsenring F, Leibing E, Kruse J, et al. Borderline personality disorder. Lancet. 2011;377(9759):74–84. doi: 10.1016/S0140-6736(10)61422-5.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Ahmad A, Sheikh S, Shah T, et al. Endoxifen, a new treatment option for mania: a double-blind, active-controlled trial demonstrates the antimanic efficacy of endoxifen. Clin Transl Sci. 2016;9(5):252–259. doi: 10.1111/cts.12407. Erratum in: Clin Transl Sci. 2017;10(2):117.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Thanvi V. Real-world long-term experience on endoxifen in bipolar disorder with psychotic symptoms. Case Rep Psychiatry. 2022;2022:3684181. doi: 10.1155/2022/3684181.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Pfohl B, Blum N, St John D, et al. Reliability and validity of the Borderline Evaluation of Severity Over Time (BEST): a self-rated scale to measure severity and change in persons with borderline personality disorder. J Pers Disord. 2009;23(3):281–293. doi: 10.1521/pedi.2009.23.3.281.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Akiskal HS. Validating ‘hard’ and ‘soft’ phenotypes within the bipolar spectrum: continuity or discontinuity? J Affect Disord. 2003;73(1–2):1–5. doi: 10.1016/s0165-0327(02)00390-7.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Krause-Utz A, Erol E, Brousianou AV, et al. Self-reported impulsivity in women with borderline personality disorder: the role of childhood maltreatment severity and emotion regulation difficulties. Borderline Personal Disord Emot Dysregul. 2019;6:6. doi: 10.1186/s40479-019-0101-8.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Eskander N, Emamy M, Saad-Omer SM, et al. The impact of impulsivity and emotional dysregulation on comorbid bipolar disorder and borderline personality disorder. Cureus. 2020;12(8):e9581. doi: 10.7759/cureus.9581.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Saunders KEA, Jones T, Perry A, et al. The influence of borderline personality traits on clinical outcomes in bipolar disorder. Bipolar Disord. 2021;23(4):368–375. doi: 10.1111/bdi.12978.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Prado-Lima PA. Tratamento farmacológico da impulsividade e do comportamento agressivo [Pharmacological treatment of impulsivity and aggressive behavior]. Braz J Psychiatry. 2009;31 Suppl 2:S58–65. doi: 10.1590/s1516-44462009000600004. Portuguese.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Chanen AM, Thompson KN. Prescribing and borderline personality disorder. Aust Prescr. 2016;39(2):49–53. doi: 10.18773/austprescr.2016.019.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Bellino S, Bozzatello P, Brignolo E, Bogetto F. Antipsychotics in the treatment of impulsivity in personality disorders and impulse control disorders. Current Psychopharmacology. 2013;2(1):5–17. doi: 10.2174/2211556011302010005</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Kim S, Lee D. Prefrontal cortex and impulsive decision making. Biol Psychiatry. 2011;69(12):1140–1146. doi: 10.1016/j.biopsych.2010.07.005.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Birnbaum SG, Yuan PX, Wang M, et al. Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science. 2004;306(5697):882–884. doi: 10.1126/science.1100021.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Ahmad A, Sheikh S, Khan MA, et al. Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder. Bipolar Disord. 2021;23(6):595–603. doi: 10.1111/bdi.13041.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Committee Opinion No. 601: Tamoxifen and uterine cancer. Obstet Gynecol. 2014;123(6):1394–1397. doi: 10.1097/01.AOG.0000450757.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Goetz MP, Suman VJ, Reid JM, et al. First-in-human phase I study of the tamoxifen metabolite z-endoxifen in women with endocrine-refractory metastatic breast cancer. J Clin Oncol. 2017;35(30):3391–3400. doi: 10.1200/JCO.2017.73.3246.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Garg S. First report of endoxifen treatment for 1 year: a case report of bipolar disorder. Int J Multispecialty Health. 2022;8(5):1–4. DOI 10.5281/zenodo.6596684.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Gowda M, Dewani K. Cost-effectiveness of endoxifen therapy in severe psychotic bipolar I disorder: a case report. Int J Appl Res. 2022;8(8):09–13.</mixed-citation></ref></ref-list></back></article>
